FDA Issues First Untitled Letter of the Year to HCT/P Manufacturer | Sheppard Mullin Richter & Hampton LLP
On March 1, 2023, the Center for Biologics Evaluation and Research (CBER) at the U.S. Food and Drug Administration (FDA) published its first untitled letter of the year to Thomas...